Canopy Growth Corporation

What they do

Canopy Growth produces and sells cannabis for medical and adult-use markets in Canada and internationally, and sells vaporizer hardware through its Storz & Bickel business. Product categories are presented as cannabis (Canada medical, Canada adult-use, and international markets) and Storz & Bickel. The company is pursuing U.S. cannabis exposure through Canopy USA, LLC, an entity tied to transactions for Wana, Jetty and, more recently, MTL Cannabis Corp. Reporting currency is the Canadian dollar.

Revenue drivers

• Canada adult-use cannabis — Largest reported cannabis line in the latest quarter at $29.7M, up 10% year over year, driven by higher flower sales from the MTL Cannabis acquisition and partly offset by lower opportunistic bulk sales.
• Canada medical cannabis — Second-largest line at $25.8M in the latest quarter, up 22% year over year, on growth in insured customers and the MTL acquisition, partly offset by a reduction in the Veterans Affairs Canada reimbursement rate.
• Storz & Bickel — Vaporizer hardware segment contributing $16.1M in the latest quarter, up 6%, with a 48% gross margin versus 29% a year earlier after a fiscal 2026 cost rationalization and a recovery of certain U.S. tariffs.
• International markets cannabis — Smallest cannabis line at $9.6M in the latest quarter, up 10%, attributed primarily to strength in Europe, specifically Poland.

Recent performance

For the quarter ended June 30, 2026 (Q1 FY2027), consolidated net revenue was $81.2M, up 13% from the prior-year period, with cannabis net revenue of $65.1M, up 14%. Consolidated gross margin was 27% versus 25%, and adjusted gross margin improved to 31% from 25%, with the current period excluding $2.6M of MTL-related inventory step-up charges. Cannabis gross margin was 22% versus 24%, while its adjusted gross margin was 26% versus 24%; Storz & Bickel gross margin rose to 48% from 29%. Selling, general and administrative expenses rose 6% year over year, attributed to the addition of MTL Cannabis.

Strategy

Management describes a push to elevate cultivation and produce a consistent, growing supply of high-quality flower for Canadian and international demand. The company is integrating MTL Cannabis, which management says is increasing high-quality flower supply, expanding revenue opportunities and realizing synergies. A stated strategic priority is accelerating entry into the U.S. cannabis market through the creation of Canopy USA, LLC, including options to acquire Jetty and arrangements involving Wana and MTL. Canopy Growth also continues to file forward-looking plans around international licensing, brand launches and its Storz & Bickel product portfolio. The company reports in Canadian dollars because the majority of operations are conducted in that currency.

Risks

• Restatement and unreliability of prior financials — The company concluded that previously issued financial statements for fiscal 2024 and 2025 and eight quarters from September 2023 through December 2025 should not be relied upon and has restated them, incurring substantial audit, legal and professional fees.
• Material weakness in internal control — Management identified a material weakness in internal control over financial reporting and concluded that internal control over financial reporting and disclosure controls were not effective as of March 31, 2026, with remediation ongoing.
• U.S. cannabis and hemp regulatory uncertainty — The company cites uncertainty over the application of U.S. state and federal law to cannabis and hemp (including CBD) products and the scope of regulation by the FDA, DEA, FTC, USPTO, USDA and state equivalents.
• Impairment and goodwill write-down risk — The company flags expectations regarding the amount or frequency of impairment losses, including write-downs of intangible assets such as goodwill, as a risk to results.

Outlook

Management says the renewed focus and momentum from the past year continued into fiscal 2027 and that clear strategies exist to deliver further growth in each end market. The company expects the MTL Cannabis integration to drive increased high-quality flower supply, expanded revenue opportunities and meaningful synergies. Management anticipates further improvement in financial results, especially in the second half of fiscal 2027, as the integration is completed.